Untersuchung einer Blasen-Chemotherapie anstelle einer Operation bei Blasenkrebs mit geringem Risiko (CALIBER)
CALIBER – Eine randomisierte Machbarkeitsstudie der Phase II zu Chemosektionen und chirurgischem Management bei nicht muskelinvasivem Blasenkrebs mit geringem Risiko
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
London, Vereinigtes Königreich, NW1 2BU
- University College Hospital
-
Manchester, Vereinigtes Königreich, M23 9LT
- Wythenshawe Hospital
-
Manchester, Vereinigtes Königreich, M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield, Cheshire, Vereinigtes Königreich, SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough, Cleveland, Vereinigtes Königreich, TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven, Cumbria, Vereinigtes Königreich, CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter, Devon, Vereinigtes Königreich, EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth, Devon, Vereinigtes Königreich, PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth, Dorset, Vereinigtes Königreich, BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester, Dorset, Vereinigtes Königreich, DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle, England, Vereinigtes Königreich, CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford, Essex, Vereinigtes Königreich, CM1 5ET
- Broomfield Hospital
-
Harlow, Essex, Vereinigtes Königreich, CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, Vereinigtes Königreich, GL53 7AN
- Cheltenham General Hospital
-
Gloucester, Gloucestershire, Vereinigtes Königreich, GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, Vereinigtes Königreich, OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke, Hampshire, Vereinigtes Königreich, RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton, Hampshire, Vereinigtes Königreich, SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford, Herefordshire, Vereinigtes Königreich, HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford, Kent, Vereinigtes Königreich, DA2 8DA
- Darent Valley Hospital
-
Gillingham, Kent, Vereinigtes Königreich, ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston, Lancashire, Vereinigtes Königreich, PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester, Leicestershire, Vereinigtes Königreich, LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow, Middlesex, Vereinigtes Königreich, HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington, Oxfordshire, Vereinigtes Königreich, OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Vereinigtes Königreich, S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich, Suffolk, Vereinigtes Königreich, IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon, Surrey, Vereinigtes Königreich, CR7 7YE
- Croydon University Hospital
-
Guildford, Surrey, Vereinigtes Königreich, GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne, Tyne and Wear, Vereinigtes Königreich, NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton, West Midlands, Vereinigtes Königreich, WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester, West Sussex, Vereinigtes Königreich, PO19 6SE
- St Richard's Hospital
-
Worthing, West Sussex, Vereinigtes Königreich, BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield, West Yorkshire, Vereinigtes Königreich, WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster, Worcestershire, Vereinigtes Königreich, DY11 6RJ
- Kidderminster Hospital
-
Redditch, Worcestershire, Vereinigtes Königreich, B98 7UB
- Alexandra Hospital
-
Worcester, Worcestershire, Vereinigtes Königreich, WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds, Yorkshire, Vereinigtes Königreich, LS9 7TF
- St James's University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
Andere Namen:
|
|
Sonstiges: Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete response rate with chemoresection
Zeitfenster: 3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Treatment compliance in chemoresection group
Zeitfenster: Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
Zeitfenster: 3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
Zeitfenster: 3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Zeitfenster: up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Zeitfenster: up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
Zeitfenster: up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
Zeitfenster: up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Männliche Urogenitalerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Urologische Neubildungen
- Erkrankungen der Harnblase
- Neoplasien der Harnblase
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Indolen
- Quinonen
- Azirinen
- Mitomycins
- Indolequinone
- Mitomycin
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ICR-CTSU/2013/10041
- 2013-005095-18 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .